Tazobactam

14,000,000 Leading Edge Experts on the ideXlab platform

Scan Science and Technology

Contact Leading Edge Experts & Companies

Scan Science and Technology

Contact Leading Edge Experts & Companies

The Experts below are selected from a list of 12678 Experts worldwide ranked by ideXlab platform

Robert K Flamm - One of the best experts on this subject based on the ideXlab platform.

  • activity of ceftolozane Tazobactam and comparators when tested against gram negative isolates collected from paediatric patients in the usa and europe between 2012 and 2016 as part of a global surveillance programme
    International Journal of Antimicrobial Agents, 2019
    Co-Authors: Dee Shortridge, Michael A Pfaller, Leonard R Duncan, Robert K Flamm
    Abstract:

    ABSTRACT Ceftolozane-Tazobactam is a combination of an antipseudomonal cephalosporin and a β-lactamase inhibitor. Ceftolozane-Tazobactam was approved by the US Food and Drug Administration in 2014 and by the European Medicines Agency in 2015 for use in adults to treat complicated urinary tract infections, acute pyelonephritis, and complicated intra-abdominal infections with metronidazole. Studies for paediatric indications are planned. The Programme to Assess Ceftolozane-Tazobactam Susceptibility monitors the resistance of ceftolozane-Tazobactam to Gram-negative isolates worldwide. In total, 6240 Gram-negative isolates were collected between 2012 and 2016 from paediatric patients (

  • antimicrobial activity of ceftolozane Tazobactam tested against enterobacteriaceae and pseudomonas aeruginosa collected from patients with bloodstream infections isolated in united states hospitals 2013 2015 as part of the program to assess ceftoloza
    Diagnostic Microbiology and Infectious Disease, 2018
    Co-Authors: Dee Shortridge, Mariana Castanheira, Michael A Pfaller, Robert K Flamm
    Abstract:

    Abstract This study evaluated the in vitro activity of ceftolozane-Tazobactam and comparators against 2647 Enterobacteriaceae and 355 Pseudomonas aeruginosa nonduplicate isolates collected from hospitalized patients with bloodstream infections in US hospitals from 2013 to 2015.Ceftolozane-Tazobactam (95.5% susceptible), amikacin (99.2% susceptible), and meropenem (98.4% susceptible) were the most active against Enterobacteriaceae. For Enterobacteriaceae, 1.4% (n = 37) were carbapenem-resistant (CRE), and 10.2% (n = 271) exhibited an extended-spectrum β-lactamase (ESBL) non-CRE phenotype. The most common ESBL enzyme detected was blaCTX-M-15-like (n = 159). Whereas ceftolozane-Tazobactam showed good activity against ESBL non-CRE phenotype Enterobacteriaceae (87.1% susceptible), it lacked useful activity against CRE strains. Ceftolozane-Tazobactam was the most potent (MIC50/90, 0.5/1 mg/L) β-lactam agent tested against P. aeruginosa isolates, with 97.5% susceptible. Only colistin was more active (98.9% susceptible). Ceftolozane-Tazobactam was the most active β-lactam agent tested against P. aeruginosa and demonstrated higher in vitro activity than available cephalosporins and piperacillin-Tazobactam when tested against Enterobacteriaceae.

  • ceftolozane Tazobactam activity against pseudomonas aeruginosa clinical isolates from u s hospitals report from the pacts antimicrobial surveillance program 2012 to 2015
    Antimicrobial Agents and Chemotherapy, 2017
    Co-Authors: Dee Shortridge, Mariana Castanheira, Michael A Pfaller, Robert K Flamm
    Abstract:

    The activity of ceftolozane-Tazobactam was compared to the activities of 7 antimicrobials against 3,851 Pseudomonas aeruginosa isolates collected from 32 U.S. hospitals in the Program to Assess Ceftolozane-Tazobactam Susceptibility from 2012 to 2015. Ceftolozane-Tazobactam and comparator susceptibilities were determined using the CLSI broth microdilution method at a central monitoring laboratory. For ceftolozane-Tazobactam, 97.0% of the isolates were susceptible. Susceptibilities of the other antibacterials tested were: amikacin, 96.9%; cefepime, 85.9%; ceftazidime, 85.1%; colistin, 99.2%; levofloxacin, 76.6%; meropenem, 81.8%; and piperacillin-Tazobactam, 80.4%. Of the 699 (18.1%) meropenem-nonsusceptible P. aeruginosa isolates, 87.6% were susceptible to ceftolozane-Tazobactam. Six hundred seven isolates (15.8%) were classified as multidrug resistant (MDR), and 363 (9.4%) were classified as extensively drug resistant (XDR). Only 1 isolate was considered pandrug resistant, which was resistant to all tested agents, including colistin. Of the 607 MDR isolates, 84.9% were ceftolozane-Tazobactam susceptible, and 76.9% of XDR isolates were ceftolozane-Tazobactam susceptible. In vitro activity against drug-resistant P. aeruginosa indicates ceftolozane-Tazobactam may be an important agent in treating serious bacterial infections.

  • antimicrobial activity of high proportion cefepime Tazobactam wck 4282 against a large number of gram negative isolates collected worldwide in 2014
    Antimicrobial Agents and Chemotherapy, 2017
    Co-Authors: Helio S Sader, Mariana Castanheira, Rodrigo E Mendes, Robert K Flamm, Ronald N Jones
    Abstract:

    Cefepime-Tazobactam (WCK 4282) is currently under clinical development for use at a dosage of 2 g/2 g every 8 h. A total of 7,981 isolates were collected from 146 medical centers (39 countries) in 2014 as a part of the SENTRY Antimicrobial Surveillance Program, and their susceptibilities to cefepime-Tazobactam (with Tazobactam at fixed concentrations of 4 and 8 μg/ml) were tested by a reference broth microdilution method. Isolates were mainly from patients with pneumonia (29.5%) and bloodstream infections (26.9%). Cefepime-Tazobactam (with Tazobactam at a fixed concentration of 8 μg/ml) and cefepime inhibited 96.9 and 87.9% of Enterobacteriaceae strains at ≤8 μg/ml. The activity of cefepime-Tazobactam against Enterobacteriaceae strains was comparable to that of meropenem (96.7% of isolates were susceptible) and greater than that of piperacillin-Tazobactam (87.7% susceptible). All Enterobacteriaceae species from the United States except Klebsiella pneumoniae had >99.0% of isolates inhibited by cefepime-Tazobactam at ≤8/8 μg/ml. The prevalence of the extended-spectrum β-lactamase (ESBL)-screening-positive phenotype was the highest among Escherichia coli isolates in China (66.3%) and among K. pneumoniae isolates (58.0%) in Latin America. Cefepime-Tazobactam at ≤8/8 μg/ml inhibited 98.7 and 71.3% of ESBL-screening-positive phenotype E. coli strains and K. pneumoniae strains, respectively. Meropenem showed limited activity against ESBL-screening-positive phenotype K. pneumoniae strains (69.6% susceptible). Cefepime-Tazobactam was active against Enterobacter spp. (MIC50 and MIC90, 0.06 and 0.5 μg/ml, respectively), including ceftazidime-nonsusceptible isolates (96.1% of isolates were inhibited by cefepime-Tazobactam at ≤8/8 μg/ml). The activity of cefepime-Tazobactam against Pseudomonas aeruginosa (82.4 and 91.6% of isolates were inhibited by cefepime-Tazobactam at ≤8/8 and ≤16/8 μg/ml, respectively) was comparable to that of meropenem and piperacillin-Tazobactam (79.2% susceptible). In summary, cefepime-Tazobactam was highly active against P. aeruginosa and Enterobacteriaceae strains, including ESBL-screening-positive phenotype E. coli strains and ceftazidime-nonsusceptible Enterobacter spp. These results support the further clinical development of the cefepime-Tazobactam combination.

  • Ceftolozane-Tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Latin America: report from an antimicrobial surveillance program (2013–2015)
    Elsevier, 2017
    Co-Authors: Michael A Pfaller, Helio S Sader, Mariana Castanheira, Dee Shortridge, Ana Gales, Robert K Flamm
    Abstract:

    This study evaluated the in vitro activity of ceftolozane-Tazobactam and comparator agents tested against Latin American isolates of Enterobacteriaceae and Pseudomonas aeruginosa from patients with health care-associated infections. Ceftolozane-Tazobactam is an antipseudomonal cephalosporin combined with a well-established β-lactamase inhibitor. A total of 2415 Gram-negative organisms (537 P. aeruginosa and 1878 Enterobacteriaceae) were consecutively collected in 12 medical centers located in four Latin American countries. The organisms were tested for susceptibility by broth microdilution methods as described by the CLSI M07-A10 document and the results interpreted according to EUCAST and CLSI breakpoint criteria. Results: Ceftolozane-Tazobactam (MIC50/90, 0.25/32 μg/mL; 84.2% susceptible) and meropenem (MIC50/90, ≤0.06/0.12 μg/mL; 92.6% susceptible) were the most active compounds tested against Enterobacteriaceae. Among the Enterobacteriaceae isolates tested, 6.6% were carbapenem-resistant Enterobacteriaceae and 26.4% exhibited an extended-spectrum β-lactamase non-carbapenem-resistant phenotype. Whereas ceftolozane-Tazobactam showed good activity against extended-spectrum beta-lactamase, non-carbapenem-resistant phenotype strains of Enterobacteriaceae (MIC50/90, 0.5/>32 μg/mL), it lacked useful activity against strains with a (MIC50/90, >32/>32 μg/mL; 1.6% S) carbapenem-resistant phenotype. Ceftolozane-Tazobactam was the most potent (MIC50//90, 0.5/16 μg/mL) β-lactam agent tested against P. aeruginosa isolates, inhibiting 86.8% at an MIC of ≤4 μg/mL. P. aeruginosa exhibited high rates of resistance to cefepime (16.0%), ceftazidime (23.6%), meropenem (28.3%), and piperacillin-Tazobactam (16.4%). Conclusions: Ceftolozane-Tazobactam was the most active β-lactam agent tested against P. aeruginosa and demonstrated higher in vitro activity than available cephalosporins and piperacillin-Tazobactam when tested against Enterobacteriaceae

Mariana Castanheira - One of the best experts on this subject based on the ideXlab platform.

  • antimicrobial activity of ceftolozane Tazobactam tested against enterobacteriaceae and pseudomonas aeruginosa collected from patients with bloodstream infections isolated in united states hospitals 2013 2015 as part of the program to assess ceftoloza
    Diagnostic Microbiology and Infectious Disease, 2018
    Co-Authors: Dee Shortridge, Mariana Castanheira, Michael A Pfaller, Robert K Flamm
    Abstract:

    Abstract This study evaluated the in vitro activity of ceftolozane-Tazobactam and comparators against 2647 Enterobacteriaceae and 355 Pseudomonas aeruginosa nonduplicate isolates collected from hospitalized patients with bloodstream infections in US hospitals from 2013 to 2015.Ceftolozane-Tazobactam (95.5% susceptible), amikacin (99.2% susceptible), and meropenem (98.4% susceptible) were the most active against Enterobacteriaceae. For Enterobacteriaceae, 1.4% (n = 37) were carbapenem-resistant (CRE), and 10.2% (n = 271) exhibited an extended-spectrum β-lactamase (ESBL) non-CRE phenotype. The most common ESBL enzyme detected was blaCTX-M-15-like (n = 159). Whereas ceftolozane-Tazobactam showed good activity against ESBL non-CRE phenotype Enterobacteriaceae (87.1% susceptible), it lacked useful activity against CRE strains. Ceftolozane-Tazobactam was the most potent (MIC50/90, 0.5/1 mg/L) β-lactam agent tested against P. aeruginosa isolates, with 97.5% susceptible. Only colistin was more active (98.9% susceptible). Ceftolozane-Tazobactam was the most active β-lactam agent tested against P. aeruginosa and demonstrated higher in vitro activity than available cephalosporins and piperacillin-Tazobactam when tested against Enterobacteriaceae.

  • ceftolozane Tazobactam activity against pseudomonas aeruginosa clinical isolates from u s hospitals report from the pacts antimicrobial surveillance program 2012 to 2015
    Antimicrobial Agents and Chemotherapy, 2017
    Co-Authors: Dee Shortridge, Mariana Castanheira, Michael A Pfaller, Robert K Flamm
    Abstract:

    The activity of ceftolozane-Tazobactam was compared to the activities of 7 antimicrobials against 3,851 Pseudomonas aeruginosa isolates collected from 32 U.S. hospitals in the Program to Assess Ceftolozane-Tazobactam Susceptibility from 2012 to 2015. Ceftolozane-Tazobactam and comparator susceptibilities were determined using the CLSI broth microdilution method at a central monitoring laboratory. For ceftolozane-Tazobactam, 97.0% of the isolates were susceptible. Susceptibilities of the other antibacterials tested were: amikacin, 96.9%; cefepime, 85.9%; ceftazidime, 85.1%; colistin, 99.2%; levofloxacin, 76.6%; meropenem, 81.8%; and piperacillin-Tazobactam, 80.4%. Of the 699 (18.1%) meropenem-nonsusceptible P. aeruginosa isolates, 87.6% were susceptible to ceftolozane-Tazobactam. Six hundred seven isolates (15.8%) were classified as multidrug resistant (MDR), and 363 (9.4%) were classified as extensively drug resistant (XDR). Only 1 isolate was considered pandrug resistant, which was resistant to all tested agents, including colistin. Of the 607 MDR isolates, 84.9% were ceftolozane-Tazobactam susceptible, and 76.9% of XDR isolates were ceftolozane-Tazobactam susceptible. In vitro activity against drug-resistant P. aeruginosa indicates ceftolozane-Tazobactam may be an important agent in treating serious bacterial infections.

  • ceftolozane Tazobactam activity against drug resistant enterobacteriaceae and pseudomonas aeruginosa causing urinary tract and intraabdominal infections in europe report from an antimicrobial surveillance programme 2012 15
    Journal of Antimicrobial Chemotherapy, 2017
    Co-Authors: Michael A Pfaller, Matteo Bassetti, Leonard R Duncan, Mariana Castanheira
    Abstract:

    Objectives To evaluate the in vitro activity of ceftolozane/Tazobactam and comparators tested against European isolates of Enterobacteriaceae and Pseudomonas aeruginosa from hospitalized patients with urinary tract infection or intraabdominal infections. Methods A total of 6553 Gram-negative organisms (603 P. aeruginosa and 5950 Enterobacteriaceae) were consecutively collected from 41 hospitals located in 17 European countries plus Israel and Turkey. The organisms were tested for susceptibility by broth microdilution methods and the results interpreted according to EUCAST and CLSI breakpoint criteria. Results Ceftolozane/Tazobactam [MIC 50/90 0.25/1 mg/L; 93.5%/91.3% susceptible (S) (CLSI/EUCAST criteria)] and meropenem [MIC 50/90 ≤0.06/≤0.06 mg/L; 98.1%/98.3% S (CLSI/EUCAST)] were the most active compounds tested against Enterobacteriaceae. Among the Enterobacteriaceae isolates, 1.9% were carbapenem resistant (CRE), 15.2% exhibited an ESBL non-CRE phenotype, 14.6% were MDR, 2.2% were XDR and 32/>32 mg/L; 3.6% S) or PDR (MIC 50 >32 mg/L; 0.0% S) phenotype. Ceftolozane/Tazobactam was the most potent (MIC 50/90 0.5/4 mg/L) β-lactam agent tested against P. aeruginosa isolates, inhibiting 91.7% at an MIC of ≤4 mg/L. P. aeruginosa exhibited high rates of resistance to cefepime (20.6%), ceftazidime (23.1%), meropenem (9.0%) and piperacillin/Tazobactam (26.9%) (EUCAST criteria). Among these four P. aeruginosa resistant phenotypes, 61.3%-70.4% were susceptible to ceftolozane/Tazobactam. Conclusions Ceftolozane/Tazobactam was the most active β-lactam agent tested against P. aeruginosa and demonstrated higher in vitro activity than currently available cephalosporins and piperacillin/Tazobactam when tested against Enterobacteriaceae.

  • antimicrobial activity of high proportion cefepime Tazobactam wck 4282 against a large number of gram negative isolates collected worldwide in 2014
    Antimicrobial Agents and Chemotherapy, 2017
    Co-Authors: Helio S Sader, Mariana Castanheira, Rodrigo E Mendes, Robert K Flamm, Ronald N Jones
    Abstract:

    Cefepime-Tazobactam (WCK 4282) is currently under clinical development for use at a dosage of 2 g/2 g every 8 h. A total of 7,981 isolates were collected from 146 medical centers (39 countries) in 2014 as a part of the SENTRY Antimicrobial Surveillance Program, and their susceptibilities to cefepime-Tazobactam (with Tazobactam at fixed concentrations of 4 and 8 μg/ml) were tested by a reference broth microdilution method. Isolates were mainly from patients with pneumonia (29.5%) and bloodstream infections (26.9%). Cefepime-Tazobactam (with Tazobactam at a fixed concentration of 8 μg/ml) and cefepime inhibited 96.9 and 87.9% of Enterobacteriaceae strains at ≤8 μg/ml. The activity of cefepime-Tazobactam against Enterobacteriaceae strains was comparable to that of meropenem (96.7% of isolates were susceptible) and greater than that of piperacillin-Tazobactam (87.7% susceptible). All Enterobacteriaceae species from the United States except Klebsiella pneumoniae had >99.0% of isolates inhibited by cefepime-Tazobactam at ≤8/8 μg/ml. The prevalence of the extended-spectrum β-lactamase (ESBL)-screening-positive phenotype was the highest among Escherichia coli isolates in China (66.3%) and among K. pneumoniae isolates (58.0%) in Latin America. Cefepime-Tazobactam at ≤8/8 μg/ml inhibited 98.7 and 71.3% of ESBL-screening-positive phenotype E. coli strains and K. pneumoniae strains, respectively. Meropenem showed limited activity against ESBL-screening-positive phenotype K. pneumoniae strains (69.6% susceptible). Cefepime-Tazobactam was active against Enterobacter spp. (MIC50 and MIC90, 0.06 and 0.5 μg/ml, respectively), including ceftazidime-nonsusceptible isolates (96.1% of isolates were inhibited by cefepime-Tazobactam at ≤8/8 μg/ml). The activity of cefepime-Tazobactam against Pseudomonas aeruginosa (82.4 and 91.6% of isolates were inhibited by cefepime-Tazobactam at ≤8/8 and ≤16/8 μg/ml, respectively) was comparable to that of meropenem and piperacillin-Tazobactam (79.2% susceptible). In summary, cefepime-Tazobactam was highly active against P. aeruginosa and Enterobacteriaceae strains, including ESBL-screening-positive phenotype E. coli strains and ceftazidime-nonsusceptible Enterobacter spp. These results support the further clinical development of the cefepime-Tazobactam combination.

  • Ceftolozane-Tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Latin America: report from an antimicrobial surveillance program (2013–2015)
    Elsevier, 2017
    Co-Authors: Michael A Pfaller, Helio S Sader, Mariana Castanheira, Dee Shortridge, Ana Gales, Robert K Flamm
    Abstract:

    This study evaluated the in vitro activity of ceftolozane-Tazobactam and comparator agents tested against Latin American isolates of Enterobacteriaceae and Pseudomonas aeruginosa from patients with health care-associated infections. Ceftolozane-Tazobactam is an antipseudomonal cephalosporin combined with a well-established β-lactamase inhibitor. A total of 2415 Gram-negative organisms (537 P. aeruginosa and 1878 Enterobacteriaceae) were consecutively collected in 12 medical centers located in four Latin American countries. The organisms were tested for susceptibility by broth microdilution methods as described by the CLSI M07-A10 document and the results interpreted according to EUCAST and CLSI breakpoint criteria. Results: Ceftolozane-Tazobactam (MIC50/90, 0.25/32 μg/mL; 84.2% susceptible) and meropenem (MIC50/90, ≤0.06/0.12 μg/mL; 92.6% susceptible) were the most active compounds tested against Enterobacteriaceae. Among the Enterobacteriaceae isolates tested, 6.6% were carbapenem-resistant Enterobacteriaceae and 26.4% exhibited an extended-spectrum β-lactamase non-carbapenem-resistant phenotype. Whereas ceftolozane-Tazobactam showed good activity against extended-spectrum beta-lactamase, non-carbapenem-resistant phenotype strains of Enterobacteriaceae (MIC50/90, 0.5/>32 μg/mL), it lacked useful activity against strains with a (MIC50/90, >32/>32 μg/mL; 1.6% S) carbapenem-resistant phenotype. Ceftolozane-Tazobactam was the most potent (MIC50//90, 0.5/16 μg/mL) β-lactam agent tested against P. aeruginosa isolates, inhibiting 86.8% at an MIC of ≤4 μg/mL. P. aeruginosa exhibited high rates of resistance to cefepime (16.0%), ceftazidime (23.6%), meropenem (28.3%), and piperacillin-Tazobactam (16.4%). Conclusions: Ceftolozane-Tazobactam was the most active β-lactam agent tested against P. aeruginosa and demonstrated higher in vitro activity than available cephalosporins and piperacillin-Tazobactam when tested against Enterobacteriaceae

Michael A Pfaller - One of the best experts on this subject based on the ideXlab platform.

  • activity of ceftolozane Tazobactam and comparators when tested against gram negative isolates collected from paediatric patients in the usa and europe between 2012 and 2016 as part of a global surveillance programme
    International Journal of Antimicrobial Agents, 2019
    Co-Authors: Dee Shortridge, Michael A Pfaller, Leonard R Duncan, Robert K Flamm
    Abstract:

    ABSTRACT Ceftolozane-Tazobactam is a combination of an antipseudomonal cephalosporin and a β-lactamase inhibitor. Ceftolozane-Tazobactam was approved by the US Food and Drug Administration in 2014 and by the European Medicines Agency in 2015 for use in adults to treat complicated urinary tract infections, acute pyelonephritis, and complicated intra-abdominal infections with metronidazole. Studies for paediatric indications are planned. The Programme to Assess Ceftolozane-Tazobactam Susceptibility monitors the resistance of ceftolozane-Tazobactam to Gram-negative isolates worldwide. In total, 6240 Gram-negative isolates were collected between 2012 and 2016 from paediatric patients (

  • antimicrobial activity of ceftolozane Tazobactam tested against enterobacteriaceae and pseudomonas aeruginosa collected from patients with bloodstream infections isolated in united states hospitals 2013 2015 as part of the program to assess ceftoloza
    Diagnostic Microbiology and Infectious Disease, 2018
    Co-Authors: Dee Shortridge, Mariana Castanheira, Michael A Pfaller, Robert K Flamm
    Abstract:

    Abstract This study evaluated the in vitro activity of ceftolozane-Tazobactam and comparators against 2647 Enterobacteriaceae and 355 Pseudomonas aeruginosa nonduplicate isolates collected from hospitalized patients with bloodstream infections in US hospitals from 2013 to 2015.Ceftolozane-Tazobactam (95.5% susceptible), amikacin (99.2% susceptible), and meropenem (98.4% susceptible) were the most active against Enterobacteriaceae. For Enterobacteriaceae, 1.4% (n = 37) were carbapenem-resistant (CRE), and 10.2% (n = 271) exhibited an extended-spectrum β-lactamase (ESBL) non-CRE phenotype. The most common ESBL enzyme detected was blaCTX-M-15-like (n = 159). Whereas ceftolozane-Tazobactam showed good activity against ESBL non-CRE phenotype Enterobacteriaceae (87.1% susceptible), it lacked useful activity against CRE strains. Ceftolozane-Tazobactam was the most potent (MIC50/90, 0.5/1 mg/L) β-lactam agent tested against P. aeruginosa isolates, with 97.5% susceptible. Only colistin was more active (98.9% susceptible). Ceftolozane-Tazobactam was the most active β-lactam agent tested against P. aeruginosa and demonstrated higher in vitro activity than available cephalosporins and piperacillin-Tazobactam when tested against Enterobacteriaceae.

  • ceftolozane Tazobactam activity against pseudomonas aeruginosa clinical isolates from u s hospitals report from the pacts antimicrobial surveillance program 2012 to 2015
    Antimicrobial Agents and Chemotherapy, 2017
    Co-Authors: Dee Shortridge, Mariana Castanheira, Michael A Pfaller, Robert K Flamm
    Abstract:

    The activity of ceftolozane-Tazobactam was compared to the activities of 7 antimicrobials against 3,851 Pseudomonas aeruginosa isolates collected from 32 U.S. hospitals in the Program to Assess Ceftolozane-Tazobactam Susceptibility from 2012 to 2015. Ceftolozane-Tazobactam and comparator susceptibilities were determined using the CLSI broth microdilution method at a central monitoring laboratory. For ceftolozane-Tazobactam, 97.0% of the isolates were susceptible. Susceptibilities of the other antibacterials tested were: amikacin, 96.9%; cefepime, 85.9%; ceftazidime, 85.1%; colistin, 99.2%; levofloxacin, 76.6%; meropenem, 81.8%; and piperacillin-Tazobactam, 80.4%. Of the 699 (18.1%) meropenem-nonsusceptible P. aeruginosa isolates, 87.6% were susceptible to ceftolozane-Tazobactam. Six hundred seven isolates (15.8%) were classified as multidrug resistant (MDR), and 363 (9.4%) were classified as extensively drug resistant (XDR). Only 1 isolate was considered pandrug resistant, which was resistant to all tested agents, including colistin. Of the 607 MDR isolates, 84.9% were ceftolozane-Tazobactam susceptible, and 76.9% of XDR isolates were ceftolozane-Tazobactam susceptible. In vitro activity against drug-resistant P. aeruginosa indicates ceftolozane-Tazobactam may be an important agent in treating serious bacterial infections.

  • ceftolozane Tazobactam activity against drug resistant enterobacteriaceae and pseudomonas aeruginosa causing urinary tract and intraabdominal infections in europe report from an antimicrobial surveillance programme 2012 15
    Journal of Antimicrobial Chemotherapy, 2017
    Co-Authors: Michael A Pfaller, Matteo Bassetti, Leonard R Duncan, Mariana Castanheira
    Abstract:

    Objectives To evaluate the in vitro activity of ceftolozane/Tazobactam and comparators tested against European isolates of Enterobacteriaceae and Pseudomonas aeruginosa from hospitalized patients with urinary tract infection or intraabdominal infections. Methods A total of 6553 Gram-negative organisms (603 P. aeruginosa and 5950 Enterobacteriaceae) were consecutively collected from 41 hospitals located in 17 European countries plus Israel and Turkey. The organisms were tested for susceptibility by broth microdilution methods and the results interpreted according to EUCAST and CLSI breakpoint criteria. Results Ceftolozane/Tazobactam [MIC 50/90 0.25/1 mg/L; 93.5%/91.3% susceptible (S) (CLSI/EUCAST criteria)] and meropenem [MIC 50/90 ≤0.06/≤0.06 mg/L; 98.1%/98.3% S (CLSI/EUCAST)] were the most active compounds tested against Enterobacteriaceae. Among the Enterobacteriaceae isolates, 1.9% were carbapenem resistant (CRE), 15.2% exhibited an ESBL non-CRE phenotype, 14.6% were MDR, 2.2% were XDR and 32/>32 mg/L; 3.6% S) or PDR (MIC 50 >32 mg/L; 0.0% S) phenotype. Ceftolozane/Tazobactam was the most potent (MIC 50/90 0.5/4 mg/L) β-lactam agent tested against P. aeruginosa isolates, inhibiting 91.7% at an MIC of ≤4 mg/L. P. aeruginosa exhibited high rates of resistance to cefepime (20.6%), ceftazidime (23.1%), meropenem (9.0%) and piperacillin/Tazobactam (26.9%) (EUCAST criteria). Among these four P. aeruginosa resistant phenotypes, 61.3%-70.4% were susceptible to ceftolozane/Tazobactam. Conclusions Ceftolozane/Tazobactam was the most active β-lactam agent tested against P. aeruginosa and demonstrated higher in vitro activity than currently available cephalosporins and piperacillin/Tazobactam when tested against Enterobacteriaceae.

  • Ceftolozane-Tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Latin America: report from an antimicrobial surveillance program (2013–2015)
    Elsevier, 2017
    Co-Authors: Michael A Pfaller, Helio S Sader, Mariana Castanheira, Dee Shortridge, Ana Gales, Robert K Flamm
    Abstract:

    This study evaluated the in vitro activity of ceftolozane-Tazobactam and comparator agents tested against Latin American isolates of Enterobacteriaceae and Pseudomonas aeruginosa from patients with health care-associated infections. Ceftolozane-Tazobactam is an antipseudomonal cephalosporin combined with a well-established β-lactamase inhibitor. A total of 2415 Gram-negative organisms (537 P. aeruginosa and 1878 Enterobacteriaceae) were consecutively collected in 12 medical centers located in four Latin American countries. The organisms were tested for susceptibility by broth microdilution methods as described by the CLSI M07-A10 document and the results interpreted according to EUCAST and CLSI breakpoint criteria. Results: Ceftolozane-Tazobactam (MIC50/90, 0.25/32 μg/mL; 84.2% susceptible) and meropenem (MIC50/90, ≤0.06/0.12 μg/mL; 92.6% susceptible) were the most active compounds tested against Enterobacteriaceae. Among the Enterobacteriaceae isolates tested, 6.6% were carbapenem-resistant Enterobacteriaceae and 26.4% exhibited an extended-spectrum β-lactamase non-carbapenem-resistant phenotype. Whereas ceftolozane-Tazobactam showed good activity against extended-spectrum beta-lactamase, non-carbapenem-resistant phenotype strains of Enterobacteriaceae (MIC50/90, 0.5/>32 μg/mL), it lacked useful activity against strains with a (MIC50/90, >32/>32 μg/mL; 1.6% S) carbapenem-resistant phenotype. Ceftolozane-Tazobactam was the most potent (MIC50//90, 0.5/16 μg/mL) β-lactam agent tested against P. aeruginosa isolates, inhibiting 86.8% at an MIC of ≤4 μg/mL. P. aeruginosa exhibited high rates of resistance to cefepime (16.0%), ceftazidime (23.6%), meropenem (28.3%), and piperacillin-Tazobactam (16.4%). Conclusions: Ceftolozane-Tazobactam was the most active β-lactam agent tested against P. aeruginosa and demonstrated higher in vitro activity than available cephalosporins and piperacillin-Tazobactam when tested against Enterobacteriaceae

Dee Shortridge - One of the best experts on this subject based on the ideXlab platform.

  • activity of ceftolozane Tazobactam and comparators when tested against gram negative isolates collected from paediatric patients in the usa and europe between 2012 and 2016 as part of a global surveillance programme
    International Journal of Antimicrobial Agents, 2019
    Co-Authors: Dee Shortridge, Michael A Pfaller, Leonard R Duncan, Robert K Flamm
    Abstract:

    ABSTRACT Ceftolozane-Tazobactam is a combination of an antipseudomonal cephalosporin and a β-lactamase inhibitor. Ceftolozane-Tazobactam was approved by the US Food and Drug Administration in 2014 and by the European Medicines Agency in 2015 for use in adults to treat complicated urinary tract infections, acute pyelonephritis, and complicated intra-abdominal infections with metronidazole. Studies for paediatric indications are planned. The Programme to Assess Ceftolozane-Tazobactam Susceptibility monitors the resistance of ceftolozane-Tazobactam to Gram-negative isolates worldwide. In total, 6240 Gram-negative isolates were collected between 2012 and 2016 from paediatric patients (

  • antimicrobial activity of ceftolozane Tazobactam tested against enterobacteriaceae and pseudomonas aeruginosa collected from patients with bloodstream infections isolated in united states hospitals 2013 2015 as part of the program to assess ceftoloza
    Diagnostic Microbiology and Infectious Disease, 2018
    Co-Authors: Dee Shortridge, Mariana Castanheira, Michael A Pfaller, Robert K Flamm
    Abstract:

    Abstract This study evaluated the in vitro activity of ceftolozane-Tazobactam and comparators against 2647 Enterobacteriaceae and 355 Pseudomonas aeruginosa nonduplicate isolates collected from hospitalized patients with bloodstream infections in US hospitals from 2013 to 2015.Ceftolozane-Tazobactam (95.5% susceptible), amikacin (99.2% susceptible), and meropenem (98.4% susceptible) were the most active against Enterobacteriaceae. For Enterobacteriaceae, 1.4% (n = 37) were carbapenem-resistant (CRE), and 10.2% (n = 271) exhibited an extended-spectrum β-lactamase (ESBL) non-CRE phenotype. The most common ESBL enzyme detected was blaCTX-M-15-like (n = 159). Whereas ceftolozane-Tazobactam showed good activity against ESBL non-CRE phenotype Enterobacteriaceae (87.1% susceptible), it lacked useful activity against CRE strains. Ceftolozane-Tazobactam was the most potent (MIC50/90, 0.5/1 mg/L) β-lactam agent tested against P. aeruginosa isolates, with 97.5% susceptible. Only colistin was more active (98.9% susceptible). Ceftolozane-Tazobactam was the most active β-lactam agent tested against P. aeruginosa and demonstrated higher in vitro activity than available cephalosporins and piperacillin-Tazobactam when tested against Enterobacteriaceae.

  • ceftolozane Tazobactam activity against pseudomonas aeruginosa clinical isolates from u s hospitals report from the pacts antimicrobial surveillance program 2012 to 2015
    Antimicrobial Agents and Chemotherapy, 2017
    Co-Authors: Dee Shortridge, Mariana Castanheira, Michael A Pfaller, Robert K Flamm
    Abstract:

    The activity of ceftolozane-Tazobactam was compared to the activities of 7 antimicrobials against 3,851 Pseudomonas aeruginosa isolates collected from 32 U.S. hospitals in the Program to Assess Ceftolozane-Tazobactam Susceptibility from 2012 to 2015. Ceftolozane-Tazobactam and comparator susceptibilities were determined using the CLSI broth microdilution method at a central monitoring laboratory. For ceftolozane-Tazobactam, 97.0% of the isolates were susceptible. Susceptibilities of the other antibacterials tested were: amikacin, 96.9%; cefepime, 85.9%; ceftazidime, 85.1%; colistin, 99.2%; levofloxacin, 76.6%; meropenem, 81.8%; and piperacillin-Tazobactam, 80.4%. Of the 699 (18.1%) meropenem-nonsusceptible P. aeruginosa isolates, 87.6% were susceptible to ceftolozane-Tazobactam. Six hundred seven isolates (15.8%) were classified as multidrug resistant (MDR), and 363 (9.4%) were classified as extensively drug resistant (XDR). Only 1 isolate was considered pandrug resistant, which was resistant to all tested agents, including colistin. Of the 607 MDR isolates, 84.9% were ceftolozane-Tazobactam susceptible, and 76.9% of XDR isolates were ceftolozane-Tazobactam susceptible. In vitro activity against drug-resistant P. aeruginosa indicates ceftolozane-Tazobactam may be an important agent in treating serious bacterial infections.

  • Ceftolozane-Tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in Latin America: report from an antimicrobial surveillance program (2013–2015)
    Elsevier, 2017
    Co-Authors: Michael A Pfaller, Helio S Sader, Mariana Castanheira, Dee Shortridge, Ana Gales, Robert K Flamm
    Abstract:

    This study evaluated the in vitro activity of ceftolozane-Tazobactam and comparator agents tested against Latin American isolates of Enterobacteriaceae and Pseudomonas aeruginosa from patients with health care-associated infections. Ceftolozane-Tazobactam is an antipseudomonal cephalosporin combined with a well-established β-lactamase inhibitor. A total of 2415 Gram-negative organisms (537 P. aeruginosa and 1878 Enterobacteriaceae) were consecutively collected in 12 medical centers located in four Latin American countries. The organisms were tested for susceptibility by broth microdilution methods as described by the CLSI M07-A10 document and the results interpreted according to EUCAST and CLSI breakpoint criteria. Results: Ceftolozane-Tazobactam (MIC50/90, 0.25/32 μg/mL; 84.2% susceptible) and meropenem (MIC50/90, ≤0.06/0.12 μg/mL; 92.6% susceptible) were the most active compounds tested against Enterobacteriaceae. Among the Enterobacteriaceae isolates tested, 6.6% were carbapenem-resistant Enterobacteriaceae and 26.4% exhibited an extended-spectrum β-lactamase non-carbapenem-resistant phenotype. Whereas ceftolozane-Tazobactam showed good activity against extended-spectrum beta-lactamase, non-carbapenem-resistant phenotype strains of Enterobacteriaceae (MIC50/90, 0.5/>32 μg/mL), it lacked useful activity against strains with a (MIC50/90, >32/>32 μg/mL; 1.6% S) carbapenem-resistant phenotype. Ceftolozane-Tazobactam was the most potent (MIC50//90, 0.5/16 μg/mL) β-lactam agent tested against P. aeruginosa isolates, inhibiting 86.8% at an MIC of ≤4 μg/mL. P. aeruginosa exhibited high rates of resistance to cefepime (16.0%), ceftazidime (23.6%), meropenem (28.3%), and piperacillin-Tazobactam (16.4%). Conclusions: Ceftolozane-Tazobactam was the most active β-lactam agent tested against P. aeruginosa and demonstrated higher in vitro activity than available cephalosporins and piperacillin-Tazobactam when tested against Enterobacteriaceae

Ronald N Jones - One of the best experts on this subject based on the ideXlab platform.

  • antimicrobial activity of high proportion cefepime Tazobactam wck 4282 against a large number of gram negative isolates collected worldwide in 2014
    Antimicrobial Agents and Chemotherapy, 2017
    Co-Authors: Helio S Sader, Mariana Castanheira, Rodrigo E Mendes, Robert K Flamm, Ronald N Jones
    Abstract:

    Cefepime-Tazobactam (WCK 4282) is currently under clinical development for use at a dosage of 2 g/2 g every 8 h. A total of 7,981 isolates were collected from 146 medical centers (39 countries) in 2014 as a part of the SENTRY Antimicrobial Surveillance Program, and their susceptibilities to cefepime-Tazobactam (with Tazobactam at fixed concentrations of 4 and 8 μg/ml) were tested by a reference broth microdilution method. Isolates were mainly from patients with pneumonia (29.5%) and bloodstream infections (26.9%). Cefepime-Tazobactam (with Tazobactam at a fixed concentration of 8 μg/ml) and cefepime inhibited 96.9 and 87.9% of Enterobacteriaceae strains at ≤8 μg/ml. The activity of cefepime-Tazobactam against Enterobacteriaceae strains was comparable to that of meropenem (96.7% of isolates were susceptible) and greater than that of piperacillin-Tazobactam (87.7% susceptible). All Enterobacteriaceae species from the United States except Klebsiella pneumoniae had >99.0% of isolates inhibited by cefepime-Tazobactam at ≤8/8 μg/ml. The prevalence of the extended-spectrum β-lactamase (ESBL)-screening-positive phenotype was the highest among Escherichia coli isolates in China (66.3%) and among K. pneumoniae isolates (58.0%) in Latin America. Cefepime-Tazobactam at ≤8/8 μg/ml inhibited 98.7 and 71.3% of ESBL-screening-positive phenotype E. coli strains and K. pneumoniae strains, respectively. Meropenem showed limited activity against ESBL-screening-positive phenotype K. pneumoniae strains (69.6% susceptible). Cefepime-Tazobactam was active against Enterobacter spp. (MIC50 and MIC90, 0.06 and 0.5 μg/ml, respectively), including ceftazidime-nonsusceptible isolates (96.1% of isolates were inhibited by cefepime-Tazobactam at ≤8/8 μg/ml). The activity of cefepime-Tazobactam against Pseudomonas aeruginosa (82.4 and 91.6% of isolates were inhibited by cefepime-Tazobactam at ≤8/8 and ≤16/8 μg/ml, respectively) was comparable to that of meropenem and piperacillin-Tazobactam (79.2% susceptible). In summary, cefepime-Tazobactam was highly active against P. aeruginosa and Enterobacteriaceae strains, including ESBL-screening-positive phenotype E. coli strains and ceftazidime-nonsusceptible Enterobacter spp. These results support the further clinical development of the cefepime-Tazobactam combination.

  • ceftolozane Tazobactam activity tested against gram negative bacterial isolates from hospitalised patients with pneumonia in us and european medical centres 2012
    International Journal of Antimicrobial Agents, 2014
    Co-Authors: David J Farrell, Helio S Sader, Robert K Flamm, Ronald N Jones
    Abstract:

    Abstract During 2012, a total of 2968 isolates were consecutively collected from 59 medical centres in the USA and 15 European countries from hospitalised patients with pneumonia. Ceftolozane/Tazobactam (Tazobactam at a fixed concentration of 4 mg/L) and comparator agents were tested by reference methods, and MIC endpoints were interpreted by CLSI (2013) and EUCAST (2013) breakpoint criteria. Pseudomonas aeruginosa was the most common isolated pathogen (1019 strains; 34.3%), and ceftolozane/Tazobactam was the most active β-lactam tested against P. aeruginosa (MIC50/90, 0.5/4 mg/L; 94.1% inhibited at ≤8 mg/L). P. aeruginosa exhibited moderate susceptibility to meropenem (MIC50/90, 0.5/>8 mg/L; 73.7% susceptible), ceftazidime (MIC50/90, 2/>32 mg/L; 73.6% susceptible), cefepime (MIC50/90, 4/>16 mg/L; 76.5% susceptible), piperacillin/Tazobactam (MIC50/90, 8/>64 mg/L; 69.5% susceptible), levofloxacin [MIC50/90, 0.5/>4 mg/L; 69.9/61.0% susceptible (CLSI/EUCAST criteria)] and gentamicin (MIC50/90, 2/>8 mg/L; 80.7% susceptible). Ceftolozane/Tazobactam exhibited activity against many ceftazidime-non-susceptible, meropenem-non-susceptible and piperacillin/Tazobactam-non-susceptible, multidrug-resistant (MDR) and extensively drug-resistant (XDR) P. aeruginosa isolates. Ceftolozane/Tazobactam was active (MIC50/90, 0.25/4 mg/L; 94.6% inhibited at ≤8 mg/L) against 1530 Enterobacteriaceae, including activity against many MDR and XDR strains. MDR and XDR prevalence varied widely between countries both for P. aeruginosa (24.1% MDR and 17.1% XDR overall) and Enterobacteriaceae (15.4% MDR and 2.7% XDR overall). All β-lactams had limited activity against Acinetobacter spp. and Stenotrophomonas maltophilia. Ceftolozane/Tazobactam demonstrated greater in vitro activity than currently available cephalosporins, carbapenems and piperacillin/Tazobactam when tested against P. aeruginosa. In addition, ceftolozane/Tazobactam demonstrated greater activity than contemporary cephalosporins and piperacillin/Tazobactam when tested against most Enterobacteriaceae.

  • relationship between ceftolozane Tazobactam exposure and drug resistance amplification in a hollow fiber infection model
    Antimicrobial Agents and Chemotherapy, 2013
    Co-Authors: Brian Vanscoy, Mariana Castanheira, Rodrigo E Mendes, Ronald N Jones, Jennifer Mccauley, Sujata M Bhavnani, Alan Forrest, Olanrewaju O Okusanya, Lawrence V Friedrich, Judith N Steenbergen
    Abstract:

    ABSTRACT In an era of rapidly emerging antimicrobial-resistant bacteria, it is critical to understand the importance of the relationships among drug exposure, duration of therapy, and selection of drug resistance. Herein we describe the results of studies designed to determine the ceftolozane-Tazobactam exposure necessary to prevent the amplification of drug-resistant bacterial subpopulations in a hollow-fiber infection model. The challenge isolate was a CTX-M-15-producing Escherichia coli isolate genetically engineered to transcribe a moderate level of bla CTX-M-15 . This organism9s bla CTX-M-15 transcription level was confirmed by relative quantitative reverse transcription-PCR (qRT-PCR), β-lactamase hydrolytic assays, and a ceftolozane MIC value of 16 mg/liter. In these studies, the experimental duration (10 days), ceftolozane-Tazobactam dose ratio (2:1), and dosing interval (every 8 h) were selected to approximate those expected to be used clinically. The ceftolozane-Tazobactam doses studied ranged from 125-62.5 to 1,500-750 mg. Negative- and positive-control arms included no treatment and piperacillin-Tazobactam at 4.5 g every 6 h, respectively. An inverted-U-shaped function best described the relationship between bacterial drug resistance amplification and drug exposure. The least- and most-intensive ceftolozane-Tazobactam dosing regimens, i.e., 125-62.5, 750-375, 1,000-500, and 1,500-750 mg, did not amplify drug resistance, while drug resistance amplification was observed with intermediate-intensity dosing regimens (250-125 and 500-250 mg). For the intermediate-intensity ceftolozane-Tazobactam dosing regimens, the drug-resistant subpopulation became the dominant population by days 4 to 6. The more-intensive ceftolozane-Tazobactam dosing regimens (750-375, 1,000-500, and 1,500-750 mg) not only prevented drug resistance amplification but also virtually sterilized the model system. These data support the selection of ceftolozane-Tazobactam dosing regimens that minimize the potential for on-therapy drug resistance amplification.

  • pharmacokinetics pharmacodynamics of Tazobactam in combination with cefepime in an in vitro infection model
    Antimicrobial Agents and Chemotherapy, 2013
    Co-Authors: Brian Vanscoy, Mariana Castanheira, Rodrigo E Mendes, Ronald N Jones, Sujata M Bhavnani, Alan Forrest, Olanrewaju O Okusanya, Anthony M Nicasio, Catharine C Bulik, Lawrence V Friedrich
    Abstract:

    We have previously demonstrated the pharmacokinetic-pharmacodynamic (PK-PD) index best associated with the efficacy of Tazobactam when used in combination with ceftolozane to be the percentage of the dosing interval during which Tazobactam concentrations remained above a threshold value (%time>threshold). Using anin vitroinfection model and the same isogenic CTX-M-15-producingEscherichia colitriplet set genetically engineered to transcribe different levels ofblaCTX-M-15, herein we describe dose fractionation studies designed to evaluate the PK-PD index associated with Tazobactam efficacy, when given in combination with piperacillin, and the impact of the presence of a different β-lactam agent, or differentblaCTX-M-15transcription levels, on the magnitude of the Tazobactam PK-PD index necessary for efficacy. The recombinant strains demonstrated piperacillin MIC values of 128, >256, and >256 μg/ml for the low-, moderate-, and high-level CTX-M-15-producingE. colistrains, respectively. The MIC value for piperacillin in the presence of 4 μg/ml of Tazobactam was 2 μg/ml for all three strains. The PK-PD index associated with Tazobactam efficacy was confirmed to be %time>threshold, regardless of β-lactamase transcription (r(2)= 0.839). The Tazobactam concentration thresholds, however, changed with the CTX-M-15 transcription level and were 0.25, 0.5, and 2 μg/ml for the low-, moderate-, and high-level CTX-M-15-producing strains, respectively (r(2)= 0.921, 0.773, and 0.875, respectively). The %time>threshold values for Tazobactam necessary for net bacterial stasis and a 1- and 2-log10-unit CFU/ml decrease from baseline at 24 h were 44.9, 62.9, and 84.9%, respectively. In addition to verifying our previous study results, these results also demonstrated that the magnitude of bacterial-cell killing associated with a β-lactam-β-lactamase inhibitor combination is dependent on the amount of β-lactamase produced. These data provide important information for the development of β-lactam-β-lactamase inhibitor combination agents.

  • pharmacokinetics pharmacodynamics of Tazobactam in combination with piperacillin in an in vitro infection model
    Antimicrobial Agents and Chemotherapy, 2013
    Co-Authors: Brian Vanscoy, Mariana Castanheira, Rodrigo E Mendes, Ronald N Jones, Sujata M Bhavnani, Alan Forrest, Olanrewaju O Okusanya, Anthony M Nicasio, Catharine C Bulik, Lawrence V Friedrich
    Abstract:

    We have previously demonstrated the pharmacokinetic-pharmacodynamic (PK-PD) index best associated with the efficacy of Tazobactam when used in combination with ceftolozane to be the percentage of the dosing interval during which Tazobactam concentrations remained above a threshold value (%time>threshold). Using anin vitroinfection model and the same isogenic CTX-M-15-producingEscherichia colitriplet set genetically engineered to transcribe different levels ofblaCTX-M-15, herein we describe dose fractionation studies designed to evaluate the PK-PD index associated with Tazobactam efficacy, when given in combination with piperacillin, and the impact of the presence of a different β-lactam agent, or differentblaCTX-M-15transcription levels, on the magnitude of the Tazobactam PK-PD index necessary for efficacy. The recombinant strains demonstrated piperacillin MIC values of 128, >256, and >256 μg/ml for the low-, moderate-, and high-level CTX-M-15-producingE. colistrains, respectively. The MIC value for piperacillin in the presence of 4 μg/ml of Tazobactam was 2 μg/ml for all three strains. The PK-PD index associated with Tazobactam efficacy was confirmed to be %time>threshold, regardless of β-lactamase transcription (r(2)= 0.839). The Tazobactam concentration thresholds, however, changed with the CTX-M-15 transcription level and were 0.25, 0.5, and 2 μg/ml for the low-, moderate-, and high-level CTX-M-15-producing strains, respectively (r(2)= 0.921, 0.773, and 0.875, respectively). The %time>threshold values for Tazobactam necessary for net bacterial stasis and a 1- and 2-log10-unit CFU/ml decrease from baseline at 24 h were 44.9, 62.9, and 84.9%, respectively. In addition to verifying our previous study results, these results also demonstrated that the magnitude of bacterial-cell killing associated with a β-lactam-β-lactamase inhibitor combination is dependent on the amount of β-lactamase produced. These data provide important information for the development of β-lactam-β-lactamase inhibitor combination agents.

Related terms

Tazobactam - 15 days free trial to Access Experts & Abstracts